Buscar
MaxCyte Inc
MXCTAñadir a la lista de seguimiento
1.050USD
0.0000.00%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
112.13MCap. mercado
PérdidaP/E TTM
Más Datos de MaxCyte Inc Compañía
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Información de MaxCyte Inc
Símbolo de cotizaciónMXCT
Nombre de la empresaMaxCyte Inc
Fecha de salida a bolsaMar 29, 2016
Director ejecutivoMasoud (Maher)
Número de empleados114
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 29
Dirección9713 Key West Avenue,
CiudadROCKVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20850
Teléfono13015175556
Sitio Webhttps://www.maxcyte.com/
Símbolo de cotizaciónMXCT
Fecha de salida a bolsaMar 29, 2016
Director ejecutivoMasoud (Maher)
Ejecutivos de MaxCyte Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
428.75K
+7.10%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
261.00K
+11.66%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
201.58K
+15.09%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
-171.43%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
82.92K
+51.93%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
81.00K
+37.56%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
70.31K
+43.26%
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Sandoval
Mr. David Sandoval
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
428.75K
+7.10%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
261.00K
+11.66%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
201.58K
+15.09%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
-171.43%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
82.92K
+51.93%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
81.00K
+37.56%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de MaxCyte Inc?
Los cinco principales accionistas de MaxCyte Inc son: Mr. Stanley C. (Stan) Erck
¿Cuántas instituciones poseen acciones de MaxCyte Inc (MXCT)?
A fecha de 2026Q1, 292 instituciones poseen acciones de MaxCyte Inc, con un valor de mercado combinado de aproximadamente 79.92M, lo que representa el 74.61% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -18927703.00.
¿Cuál es la mayor fuente de ganancias de MaxCyte Inc?
El 2026Q1, el segmento empresarial Product sales generó la ganancia más alta para MaxCyte Inc, ascendiendo a 18.69M y representando el 56.59% de la ganancia total.